Novartis AG
ANTIBODIES TARGETING CD32B AND METHODS OF USE THEREOF
Last updated:
Abstract:
The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.
Status:
Application
Type:
Utility
Filling date:
23 Oct 2018
Issue date:
11 Feb 2021